Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
May 25, 2024 09:40 ET
|
Vera Therapeutics
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract;Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater...
Merus kündigt Veröffentlichung eines Abstracts zu Petosemtamab mit Pembrolizumab als Erstlinienbehandlung von rezidivierenden/metastasierten Kopf- und Halstumoren der ASCO®-Jahrestagung 2024 an
May 24, 2024 21:30 ET
|
Merus N.V.
- 60%ige Ansprechrate bei 10 auswertbaren Patienten beobachtet - Günstiges Sicherheitsprofil bei 26 Patienten, die bis zum Stichtag des Abstracts eingeschlossen waren, wobei keine signifikanten...
Merus : publication d’un résumé sur l’association pétosemtamab + pembrolizumab dans le traitement de 1re ligne du CETC r/m lors de l’édition 2024 du congrès ASCO®
May 24, 2024 21:30 ET
|
Merus N.V.
- Taux de réponse de 60 % observé auprès de 10 patients évaluables - Profil d’innocuité favorable chez 26 patients recrutés à la date de clôture du résumé, sans aucune observation de...
Merus kündigt die Veröffentlichung von Abstracts für die Präsentation auf der ASCO®-Jahrestagung 2024 an
May 24, 2024 21:08 ET
|
Merus N.V.
MCLA-145 als Monotherapie und in Kombination mit Pembrolizumab – Präsentation im mündlichen Kurzvortrag: 2. Juni 2024, 11:30–13:00 Uhr CTMCLA-129 in NSCLC mit c-MET Exon 14-Skipping-Mutations –...
Merus annonce la publication des résumés qui seront présentés à la réunion annuelle 2024 de l’ASCO®
May 24, 2024 21:08 ET
|
Merus N.V.
Présentation orale rapide du MCLA-145 en monothérapie et en association avec le pembrolizumab : 2 juin 2024, 11 h 30-13 h, heure centralePrésentation sur affiche du MCLA-129 dans le cancer bronchique...
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
May 24, 2024 16:15 ET
|
Sobi, Inc.
Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
May 24, 2024 15:16 ET
|
Sobi, Inc.
FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS
Dr. Robert Corkern Launches Groundbreaking Scholarship to Foster Future Rural Healthcare Leaders in Underserved Communities
May 24, 2024 12:07 ET
|
Dr. Robert Corkern Scholarship
GREENVILLE, Ms., May 24, 2024 (GLOBE NEWSWIRE) -- Dr. Robert Corkern, MD, a respected expert in emergency and internal medicine, proudly announces the establishment of the Dr. Robert Corkern...
Hometown Hero Honors Vets on Memorial Day By Donating a Portion of Holiday Sales to K9s For Warriors
May 24, 2024 11:34 ET
|
Hometown Hero CBD
AUSTIN, Texas, May 24, 2024 (GLOBE NEWSWIRE) -- Hometown Hero, the veteran-supporting cannabusiness of hemp-derived THC and cannabidiol-based products, today announced it will donate 10% of all sales...
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024 10:00 ET
|
Apellis Pharmaceuticals, Inc.
Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were clearedHighlighted as late-breaking...